AmpliMed Corporation Reports Results from AMP-019; A Randomized Double Blind Trial of Gemcitabine/Placebo vs. Gemcitabine/Amplimexon in Advanced Pancreatic Cancer
7/12/2010 10:44:11 AM
More...
|
AmpliMed Corporation Announces License Agreement with Handok Pharmaceuticals for Exclusive Rights to Cancer Therapeutic Amplimexon(R) in Korea
9/10/2008 6:26:38 AM
More...
|
AmpliMed Corporation to Present Clinical Data from Three Clinical Trials of Amplimexon® at American Society of Clinical Oncology Annual Meeting
5/30/2008 10:19:43 AM
More...
|
AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer
5/1/2008 10:13:29 AM
More...
|
AmpliMed Corporation Secures $8.5M In Additional Series B Financing; Oncology Drug Development Company To Use Funds To Achieve Milestones In Clinical Development
11/28/2006 9:58:47 AM
More...
|
AmpliMed Corporation To Present Positive Phase I Study Results For Amplimexon(R) (imexon for inj.) In Patients With Advanced Solid Tumors
11/10/2006 10:26:00 AM
More...
|
AmpliMed Corporation Announces Interim Phase I/II Trial Results For Amplimexon Plus Dacarbazine For Treatment Of Malignant Melanoma
9/14/2006 2:09:42 PM
More...
|
AmpliMed Corporation Announces Interim Phase I/II Trial Results For Amplimexon plus Dacarbazine For Treatment Of Malignant Melanoma; Encouraging Data Presented At Perspectives In Melanoma X And The Third International Melanoma Research Congress In The Netherlands
9/14/2006 9:57:50 AM
More...
|
AmpliMed Corporation Initiates Phase I Clinical Study Of Benzimate In Patients With Advanced Refractory Cancer
4/28/2006 1:18:10 PM
More...
|
AmpliMed Corporation Begins Enrollment Of Phase I Trial Of Amplimexon In Patients With Multiple Myeloma
3/28/2006 12:29:26 PM
More...
|
|